How India Exports Chondroitin to the World

In the United States, chondroitin sulfate is predominantly marketed as a dietary supplement and is not subject to the same rigorous approval processes as pharmaceutical drugs. Consequently, there are no approved Abbreviated New Drug Applications (ANDAs) for chondroitin sulfate listed in the FDA's Orange Book. This classification allows for a more streamlined regulatory pathway for Indian exporters aiming to enter the U.S. market. However, compliance with the Dietary Supplement Health and Education Act (DSHEA) of 1994 is mandatory, necessitating adherence to Good Manufacturing Practices (GMP) and accurate labeling standards.

The absence of import alerts or significant regulatory actions against chondroitin sulfate products underscores a stable regulatory environment. Given the 71 active Indian exporters, the U.S. market presents a viable opportunity for expansion, provided that exporters maintain stringent quality control measures and comply with FDA regulations.

Within the European Union and the United Kingdom, chondroitin sulfate is also primarily marketed as a dietary supplement. As such, it does not require marketing authorization from the European Medicines Agency (EMA) or the UK's Medicines and Healthcare products Regulatory Agency (MHRA). Nevertheless, compliance with EU Directive 2002/46/EC on food supplements is essential, which includes adherence to safety, labeling, and composition standards.

Manufacturers exporting to these regions must ensure that their production facilities meet the EU's Good Manufacturing Practice (GMP) requirements, as outlined in EudraLex Volume 4. This compliance is critical to facilitate market entry and maintain consumer trust.

Chondroitin sulfate is not listed in the World Health Organization's (WHO) Model List of Essential Medicines, indicating its classification as a non-essential medicine. Consequently, it is not subject to the WHO Prequalification Programme. However, adherence to international pharmacopoeia standards, such as those set forth in the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), is crucial. These standards ensure product quality and consistency, which are vital for market acceptance and regulatory compliance.

In India, chondroitin sulfate is classified as a dietary supplement and is not listed under Schedules H, H1, or X of the Drugs and Cosmetics Act, indicating it is available over the counter (OTC). As such, it is not subject to price control measures by the National Pharmaceutical Pricing Authority (NPPA) and does not have a ceiling price under the Drug Price Control Order (DPCO). For export purposes, obtaining a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) is typically required, ensuring compliance with export regulations.

Chondroitin sulfate is a well-established compound with no active patents or exclusivity rights, allowing for robust generic competition. This status enables multiple manufacturers to produce and export the compound without infringement concerns, fostering a competitive market environment.

In February 2025, the Government Chemist published a critical review titled "Chondroitin Sulfate: A Critical Review of Generic and Specific Problems in Its Characterization and Determination." This review addresses challenges in the authentication of chondroitin-containing supplements, highlighting the need for stringent quality control measures to prevent adulteration and ensure product integrity. (gov.uk)

In November 2025, the UK's Food Standards Agency (FSA) implemented the Genetic Technology (Precision Breeding) Regulations 2025, allowing businesses to apply for Precision Bred Organism (PBO) food and feed marketing authorizations. While this regulation primarily pertains to genetically modified organisms, it underscores the evolving regulatory landscape for food and dietary supplements, potentially impacting future classifications and requirements for products like chondroitin sulfate. (food.gov.uk)

These developments emphasize the importance of continuous monitoring of regulatory changes and adherence to quality standards to maintain market access and consumer trust.

India's pharmaceutical industry, including the production of chondroitin, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of India's API and KSM requirements are sourced from China, underscoring a significant dependency. This reliance exposes the supply chain to vulnerabilities, particularly when Chinese manufacturers face operational disruptions due to environmental regulations or other factors. For instance, in July 2018, shutdowns of Chinese chemical plants led to increased prices and supply constraints for Indian pharmaceutical companies.

To mitigate this dependency, the Indian government has initiated the Production Linked Incentive (PLI) scheme, aiming to bolster domestic production of critical APIs and KSMs. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and Clavulanic Acid, marking a significant step toward reducing import reliance. However, the effectiveness of these initiatives in addressing the broader dependency on Chinese imports remains to be fully realized.

Our proprietary trade data indicates that the top five exporters of chondroitin from India account for 61.7% of the total export value, with PANACEA BIOTEC PHARMA LIMITED leading at a 17.2% share. This concentration suggests a moderate risk, as disruptions affecting these key suppliers could significantly impact the global chondroitin supply chain. While the PLI scheme aims to diversify and strengthen domestic manufacturing capabilities, its current focus on specific APIs and KSMs may not directly address the supply chain risks associated with chondroitin.

Recent geopolitical tensions have exacerbated supply chain vulnerabilities. In February 2026, the closure of the Strait of Hormuz following military conflicts disrupted global shipping routes, leading to delays and increased costs for pharmaceutical exports from India. Similarly, instability in the Red Sea region has forced shipping companies to reroute vessels around the Cape of Good Hope, adding significant transit times and expenses. These disruptions have heightened concerns about the resilience of pharmaceutical supply chains, prompting regulatory bodies like the FDA to monitor and address potential shortages.

• Diversify API and KSM Sources: Encourage the development of alternative suppliers in different geographic regions to reduce dependency on a single country.

• Enhance Domestic Production: Expand the scope of the PLI scheme to include APIs and KSMs critical to chondroitin production, fostering self-reliance.

• Strengthen Supplier Relationships: Establish long-term contracts with multiple suppliers to ensure a stable supply chain and mitigate risks associated with supplier concentration.

• Monitor Geopolitical Developments: Implement a robust system for tracking geopolitical events that could impact shipping routes and adjust logistics strategies accordingly.

• Invest in Supply Chain Resilience: Develop contingency plans, including alternative transportation routes and inventory buffers, to manage potential disruptions effectively.

RISK_LEVEL: MEDIUM